96. Crohn disease Clinical trials / Disease details
Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01489943 (ClinicalTrials.gov) | September 19, 2011 | 1/12/2011 | A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects | A Single Centre, Single Sequence, Open-Label, Repeat-Dose Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects | Crohn's Disease | Drug: GSK1605786 500 mg;Drug: Midazolam 3 mg;Drug: Pioglitazone 15 mg;Drug: Omeprazole 40 mg;Drug: Rosuvastatin 10 mg | GlaxoSmithKline | NULL | Completed | 18 Years | 55 Years | All | 24 | Phase 1 | United States |
2 | JPRN-UMIN000002074 | 2009/07/01 | 01/07/2009 | Rosuvastatin for Acute Systemic Crohn's disease: A mono-center randomized triaL | Rosuvastatin for Acute Systemic Crohn's disease: A mono-center randomized triaL - RASCAL study | Crohn's disease | Rosuvastatin (Crestor) 0mg/day: Control group Rosuvastatin (Crestor) 5mg/day: Low-dose group Rosuvastatin (Crestor) 20mg/day: High-dose group | Department of lower gastroenterology, Hyogo College of Medicine | NULL | Complete: follow-up complete | 20years-old | 65years-old | Male and Female | 45 | Phase 2 | Japan |